Licensing status

Publication and contact information

Pulmonary disease

Chronic obstructive pulmonary disease (COPD)

Integrin aVb8

Mouse and in vitro studies suggest an optimized anti-integrin aVb8 antibody could help treat COPD. In a mouse model of COPD engineered to express human integrin b8, an anti-integrin aVb8 mAb decreased inflammation and fibrosis compared with isotype control IgG. In vitro and structural analysis revealed that the mAb caused integrin aVb8 heterodimers to adopt a low-affinity conformation that prevented activation of transforming growth factor-b1 (TGFB1). Next steps include compound optimization including pharmacokinetic and biodistribution analysis toxicity studies and production to scale.

SciBX 7(28); doi:10.1038/scibx.2014.836
Published online July 24, 2014

Patent applications filed covering the COPD mouse model and antibody; mouse model available for licensing

Minagawa, S. et al. Sci. Transl. Med.; published online June 18, 2014;
Contact: Stephen L. Nishimura, University of California, San Francisco, Calif.